
German health minister Jens Spahn calls for faster adoption of biosimilars
pharmafile | November 14, 2018 | News story | Research and Development | AbbVie, Germany, biosimilars, jens Spahn
Germany’s health minister Jens Spahn has called for faster uptake of biosimilars in an effort to cut the cost of healthcare in Germany.
“Where there is a more affordable alternative at the same quality, we have to use it. Otherwise we won’t be able to sustain the high quality of pharmaceutical supply in Germany,” Spahn said.
Spahn, who has been pointed to as a potential successor to Angela Merkel, called for the faster adoption of the biological copies, after it was revealed that biosimilars would have saved the healthcare system €279 million last year.
The call has coincided with the entrance into the market of biosimilar versions of AbbVie’s Humira, which brought in $18 billion in sales last year.
Louis Goss
Related Content

Genmab to submit FDA application for lymphoma therapy
Global biotechnology company Genmab plans to submit a supplemental Biologics License Application (sBLA) to the …

The National Institute for Health and Care Excellence announce technology appraisal guidance recommending risankizumab for adult patients with moderate to severe ulcerative colitis
The National Institute for Health and Care Excellence (NICE) have recommended adult patients in England …

Abbvie acquires Cerevel Therapeutics
Abbvie has announced the acquisition of Cerevel Therapeutics, strengthening its neuroscience pipeline. Cerevel has multiple …






